News & Updates

Show Multimedia Only

Niraparib maintenance yields favourable OS trend in patients with ovarian cancer

12 Apr 2024 by

Maintenance treatment with niraparib, a potent, highly selective PARP* inhibitor, provides a favourable overall survival (OS) trend compared with placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), regardless of germline BRCA (gBRCA) mutation status, according to the ﬁnal analysis of the NORA trial presented at SGO 2024.

Niraparib maintenance yields favourable OS trend in patients with ovarian cancer

12 Apr 2024

Survival outcomes similar between minimally invasive interval debulking surgery and laparotomy

05 Apr 2024 by

A minimally invasive approach to interval debulking surgery appears to be just as effective as the use of an open technique for epithelial ovarian cancer, with no significant difference in overall survival (OS) when complete tumour resection is achieved, according to a study.

Survival outcomes similar between minimally invasive interval debulking surgery and laparotomy

05 Apr 2024

Noninvasive device targets precancerous cervical lesions with minimal risk

04 Apr 2024 by

A novel device that integrates hexaminolevulinate (HAL) hydrochloride (HCl) with photodynamic therapy for the treatment of cervical histologic high-grade squamous intraepithelial lesions (HSIL) has shown good results in the global phase III APRICITY study, with lasting efficacy and an acceptable safety profile.

Noninvasive device targets precancerous cervical lesions with minimal risk

04 Apr 2024

Vitamin B12 supplementation improves human milk status in mothers

02 Apr 2024

Maternal supplementation with vitamin B12 provides benefits on both short- and long-term human milk (HM) status, as shown in a study.

Vitamin B12 supplementation improves human milk status in mothers

02 Apr 2024

Prenatal topiramate not associated with autism in offspring

02 Apr 2024 by

Prenatal exposure to topiramate does not increase the risk of autism in offspring, a US nationwide cohort study has shown.

Prenatal topiramate not associated with autism in offspring

02 Apr 2024

Pembrolizumab plus chemo ups survival in advanced endometrial cancer across MMR subgroups

02 Apr 2024 by

Adding pembrolizumab to standard chemotherapy resulted in a favourable overall survival (OS) benefit in patients with advanced or recurrent endometrial cancer compared with chemotherapy alone, regardless of mismatch repair (MMR) status, according to a key prespecified secondary analysis of the NRG-GY018 trial presented at the SGO 2024.

Pembrolizumab plus chemo ups survival in advanced endometrial cancer across MMR subgroups

02 Apr 2024

Is it safe to use vedolizumab, ustekinumab during pregnancy?

27 Mar 2024

Pregnant women who are being treated with ustekinumab or vedolizumab appear to experience no greater complications as those receiving antitumour necrosis factor (anti-TNF) agents, immunomodulators, or combination anti-TNF/immunomodulators, according to a study.

Is it safe to use vedolizumab, ustekinumab during pregnancy?

27 Mar 2024

Vitamin D falls short of improving sexual function in PCOS

25 Mar 2024

Vitamin D supplementation does not appear to affect sexual dysfunction, while hormonal contraception (HC) appears to improve sexual function in women with polycystic ovary syndrome (PCOS), suggests a recent study.

Vitamin D falls short of improving sexual function in PCOS

25 Mar 2024

RF+PEFM safely improves vulvovaginal atrophy symptoms

24 Mar 2024

A device that combines radiofrequency (RF) with pulsed electromagnetic field–based device (PEMF) appears safe to use and has been shown to improve symptoms related to vulvovaginal atrophy (VVA) as well as female sexual function, reports a study. In addition, the nonablative, noncoagulative multipolar RF/PEMF device yields high satisfaction from women.

RF+PEFM safely improves vulvovaginal atrophy symptoms

24 Mar 2024

Original New Drug Application Approvals by US FDA (1-15 March 2024)

20 Mar 2024

New drug applications approved by US FDA as of 1-15 March 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 March 2024)

20 Mar 2024

News & Updates

Showing Obstetrics & Gynaecology articles

Showing

Specialty:

Niraparib maintenance yields favourable OS trend in patients with ovarian cancer

Niraparib maintenance yields favourable OS trend in patients with ovarian cancer

Survival outcomes similar between minimally invasive interval debulking surgery and laparotomy

Survival outcomes similar between minimally invasive interval debulking surgery and laparotomy

Noninvasive device targets precancerous cervical lesions with minimal risk

Noninvasive device targets precancerous cervical lesions with minimal risk

Vitamin B12 supplementation improves human milk status in mothers

Vitamin B12 supplementation improves human milk status in mothers

Prenatal topiramate not associated with autism in offspring

Prenatal topiramate not associated with autism in offspring

Pembrolizumab plus chemo ups survival in advanced endometrial cancer across MMR subgroups

Pembrolizumab plus chemo ups survival in advanced endometrial cancer across MMR subgroups

Is it safe to use vedolizumab, ustekinumab during pregnancy?

Is it safe to use vedolizumab, ustekinumab during pregnancy?

Vitamin D falls short of improving sexual function in PCOS

Vitamin D falls short of improving sexual function in PCOS

RF+PEFM safely improves vulvovaginal atrophy symptoms

RF+PEFM safely improves vulvovaginal atrophy symptoms

Original New Drug Application Approvals by US FDA (1-15 March 2024)

Original New Drug Application Approvals by US FDA (1-15 March 2024)